Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Vanda Pharmaceuticals acquires U.S. and Canadian rights to Ponvory (ponesimod), a selective S1P1R modulator, approved for patients with relapsing multiple sclerosis

Written by | 15 Dec 2023

Vanda Pharmaceuticals Inc. announced that it has acquired U.S. and Canadian rights to Ponvory (ponesimod) from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company. Ponvory is approved… read more.

European Commission approves Ponvory a once daily, oral therapy for the treatment of relapsing forms of multiple sclerosis – Janssen

Written by | 31 May 2021

Janssen, the Pharmaceutical Companies of Johnson & Johnson, announced that the European Commission (EC) has approved Ponvory (ponesimod) for the treatment of adult patients with relapsing multiple sclerosis… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.